Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Devgen, Alnylam, Alcon, and More


Title: Methods and Compositions for Increasing RNA Interference

Patent Number: 8,865,668

Filed: Feb. 20, 2009

Lead Inventor: Romaan Raemaekers, Devgen (Syngenta)

Title: RNAi-mediated Inhibition of TNA-alpha Signaling Pathway for Treatment of Glaucoma

Patent Number: 8,865,670

Filed: Feb. 10, 2011

Lead Inventor: Jon Chatterton, Alcon

Title: RNAi-mediated Inhibition of Spleen Tyrosine Kinase-related Inflammatory Conditions

Patent Number: 8,865,671

Filed: June 30, 2011

Lead Inventor: John Yanni, Alcon

Title: Compositions and Methods for Silencing Apolipoprotein B

Patent Number: 8,865,675

Filed: May 12, 2011

Lead Inventor: James Heyes, Protiva Biotherapeutics (Tekmira Pharmaceuticals)

Title: Methods and Kits for Synthesis of siRNA Expression Cassettes

Patent Number: 8,865,676

Filed: Jan. 31, 2013

Lead Inventor: John Rossi, City of Hope

Title: iRNA Agents with Biocleavable Tethers

Patent Number: 8,865,677

Filed: March 22, 2013

Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

Title: microRNA Fingerprints during Human Megakaryocytopoiesis

Patent Number: 8,865,885

Filed: June 25, 2013

Lead Inventor: Carlo Croce, Ohio State University

Title: Method for Downregulating Gene Expression in Fungi

Patent Number: 8,865,968

Filed: May 12, 2010

Lead Inventor: Marc Van De Craen, Devgen (Syngenta)